One example of this is endocrine therapy, which uses the selective estrogen receptor modulator tamoxifen to target and restrict the proliferation of breast cancer cells that are positive for the estrogen receptor (ER), ultimately leading to their cell death by apoptosis (Li et al., 2017). Here, ESR1 is linked to breast carcinoma.